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ADDRESSING THE REQUIREMENTS OF HOSPITAL TECHNOLOGY ASSESSMENT 
COMMITTEES IN AN ERA OF COST CONTAINMENT: EVIDENCE-BASED VALUE 
STRATEGIES FOR MEDICAL DEVICES  
Ferko N1, Saadi R2, Cameron HL1, Grima DT1 
1Cornerstone Research Group, Burlington, ON, Canada, 2Johnson & Johnson, Raritan, NJ, USA  
The medical device industry is growing rapidly, with an estimated market over 
$300 billion globally. At the same time, cost containment pressures have 
translated into hospitals creating new decision-making processes and structures 
to control costs. In many hospitals, technology assessment committees (TACs), 
or value analysis committees (VACs), are a central feature of these cost 
containment strategies for medical devices. The question of what constitutes 
current decision-making processes and evidence needs of TACs/VACs, and more 
importantly, how evidence can best be communicated and leveraged, is central 
to the successful adoption of medical devices within hospitals. Our aim was to 
provide insight into evolving global hospital TAC/VAC requirements and to 
recommend a framework to deliver these requirements. A literature review was 
undertaken, in conjunction with case studies, to identify current TAC/VAC 
processes, member perspectives, decision-making factors (including evidence 
needs), and key challenges. Based on this evidence, a conceptual framework was 
developed which is composed of a systematic set of activities pertaining to 
“identifying”, “demonstrating” and “communicating” medical device value for 
enhanced product adoption. Central components of this framework, which have 
been tested in the field, include development of concise evidence-based payer 
dossiers and value messages, as well as sales force models that encompass both 
clinical and economic endpoints. Case studies of such tools, developed across 
diverse therapeutic areas (e.g., cardiovascular disease stenting, laparoscopic 
surgery), illustrate common and essential components. These include the need 
for indirect comparison methods when head-to-head comparative effectiveness 
data are lacking for appropriate medical device alternatives. In addition, data on 
outcomes relevant to the hospital from a cost-efficiency and quality 
improvement standpoint must be integrated. Testing of these tools has 
underscored the importance of customization of model parameters to hospital 
settings.  
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THE USE OF DALYS AND QALYS IN COST-EFFECTIVENESS ANALYSIS  
Deshmukh AA1, Chen A2, Sonawane KB3, Cantor SB1 
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2Rice University, Houston, 
TX, USA, 3Auburn University, Auburn, AL, USA  
Quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) are 
summary health measures used in resource allocation decision making. 
However, the optimal choice of which summary measure to use in economic 
evaluations is unclear. On the basis of previously published literature, we 
attempt to clarify the use of summary health measures in cost-effectiveness 
analysis and recommend which summary measure to use for a given context. 
The selection of a summary health measure in cost-effectiveness analysis (CEA) 
depends to some extent on the philosophical background of the summary heath 
measures. Researchers may decide which measure to use based on the following 
selection criteria including but not limited to: 1) Purpose of research: DALYs are 
preferred for broader use in cost-effectiveness analysis, e.g., sectoral or 
generalized cost-effectiveness analysis. On the other hand, quality-adjusted life 
years (QALYs) are preferred for clinical decision making, evaluation of new 
clinical strategies, or program evaluation. 2) Norms: DALYs are preferably used 
in developing countries, whereas QALYs are the preferred outcome measure for 
conducting CEA in developed countries. 3) Availability of resources: The selection 
of a summary health measure is often driven by the availability of resources. 
Researchers in developing countries have limited resources in terms of funding 
to conduct CEAs using QALYs. On the other hand, disability weights representing 
population samples are easily accessible to researchers, which facilitate the use 
of DALYs as an outcome measure. The selection criteria for determining which 
summary health measure to use in CEA often overlap. The ultimate choice of 
summary measure should be based on the prioritization of goals and the 
availability of resources for the study.  
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INVOLVING PATIENTS AND THE PUBLIC IN HEALTH TECHNOLOGY 
ASSESSMENT IN BRAZIL  
Silva AS 
Brazilian Ministry of Health, Brasilia, Brazil  
Health Technology Assessment (HTA) is a multidisciplinary field of policy 
analysis that examines the clinical, social, ethical, and economic implications of 
the development, diffusion, and use of technology in health care, taking into 
consideration aspects such as efficiency, effectiveness, safety, cost, and cost-
effectiveness, among others. Although HTA should primarily consider the social, 
ethical, and legal impacts associated with technology, other basic attributes 
(efficacy, effectiveness, safety, and cost) end up taking precedence over the 
previous ones. But with the increasing emphasis on the engagement of patients 
as full partners in taking care of their own health, there is a need to establish 
effective means for their involvement in the decision-making process. The 
participation of society in HTA is crucial and needs to be implemented. In Brazil, 
community participation is one of the guidelines of the Brazilian Public Health 
System (SUS) present in the Federal Constitution of 1988. It’s also one of the 
principles outlined in Laws 8,080/1990 and 8,142/1990, that provide for 
community participation in the SUS. In 2011, Law 12,401 was enacted, 
officializing the participation of civil society in the process of incorporating 
technologies in the health system. However, it is necessary to analyze, discuss, 
and question how to actually introduce the patient and public preferences into 
HTA processes and in the process of incorporating new health technologies 
within the current Brazilian context (SUS perspective), given how important the 
broad suitability of new health technologies is. This is the aim of an ongoing 
study that will provide guidance to support HTA units in the Brazilian Ministry of 
Health and abroad in their decisions regarding patient participation.  
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NEW PERSONALIZED HEALTH CARE APPROACH: ENGAGING PROSTATE 
CANCER PATIENTS, PROVIDERS, AND PAYERS  
Drea EJ1, Pitluk H2, Thompson S3, Michelet K4 
1Sanofi Oncology, Phoenix, AZ, USA, 2Health Services Advisory Group, Inc., Phoenix, AZ, USA, 
3Sanofi Oncology, Bridgewater, NJ, USA, 4Sanofi, Scottsdale, AZ, USA  
OBJECTIVES: Creating interventions that engage/educate prostate cancer (PCa) 
patients and caregivers is an integral part of enhanced quality of care. A PCa 
management tool is intended to serve as a mechanism for more effective 
transitioning of patients through stages of care. Moreover, the development of a 
single-stop resource compendium is intended to objectively define quality care 
so that patients have a better understanding of their diagnosis and choices via a 
format that is not only easily understood but also enhances communication and 
trust with their health care providers (HCPs). METHODS: Part 1-Build a single 
source, web-based compendium of PCa resources for patients and caregivers, 
HCPs, and payers designed to engage and educate patients, facilitate 
understanding of treatment strategies, empower patients to work closely with 
their HCPs, and provide patients with resources and tools that enable enhanced 
quality decision-making. In addition the compendium will draw attention to the 
subset of patients, a disproportionate number of whom are from disparity or 
underserved populations, by identifying ways to address their unique needs. Part 
2-Develop a predictive model for PCa management that incorporates geographic 
variation in morbidity and mortality for PCa patients and provides customized 
pathway choices for treatment sequencing. RESULTS: (IN PROCESS) By 2020 
there will be a disproportionate increase in patient demand for cancer services, 
compared with the estimated 14% increase in oncology health care professionals 
available to support patients. In 2015 the Commission on Cancer (COC) will 
require providers to meet new standards to evaluate patients in distress placing 
additional stress on the current system. Under the Affordable Care Act (ACA), 
providers will be assuming more responsibility for patient behaviors and 
outcomes. In recognition of these challenges and timing of events we present the 
progress in the development of tools and interventions that can serve as an 
integral step in future patient-centered PCa care.  
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OPERATIONALISING MULTIPLE CRITERIA DECISION ANALYSIS FOR HEALTH 
TECHNOLOGY ASSESSMENT  
Thokala P 
University of Sheffield, Sheffield, UK  
OBJECTIVES: To discuss the different methods of multi criteria decision analysis 
(MCDA) that could be used in health technology assessment (HTA) and their 
relative merits. The current practice of health technology appraisals is based on 
the incremental cost-effectiveness ratio (ICER). Even though other factors (e.g. 
severity, life saving, etc) are considered along with ICERs, there is concern that 
its approach may fail to capture other important sources of value. MCDA is 
aimed at supporting decision makers faced with evaluating alternatives taking 
into account multiple, and often conflictive, criteria in an explicit manner. 
METHODS: This paper begins with a critical review of state-of-the-art methods 
for incorporating multiple criteria in health technology assessment (HTA). A 
number of important questions are addressed to identify the most appropriate 
MCDA method that might be used to support decision making. For example, 
what criteria should be incorporated? Whose weights should be used and how to 
elicit them? How to incorporate uncertainty into the MCDA process? What 
should the ‘basic’ cost-effectiveness threshold be? This paper will discuss these 
questions, outline and assess methodological issues that would be raised by the 
use of MCDA in health technology assessment (HTA). RESULTS: MCDA does not 
just stop at simple weighting and scoring; more flexible approaches are available 
that appear to be more relevant to health technology appraisal and value based 
pricing (VBP). A potential MCDA approach for HTA is to calculate “weighted” 
QALYs from the QALY weights which reflect the broader value of the product’s 
benefits and compare against the updated “basic threshold” value. 
CONCLUSIONS: There are general practical issues that might arise from using 
this MCDA approach in the HTA process and further research needs to be 
performed to address the issues identified in order to ensure the success of this 
MCDA technique in the appraisal process.  
 
PHP160  
THE MOBILE TECHNOLOGY FOR COMMUNITY HEALTH (MOTECH) 
INITIATIVE:AN M-HEALTH SYSTEM PILOT IN A RURAL DISTRICT OF 
NORTHERN GHANA  
Awoonor-Williams JK 
Ghana Health Service, Upper East Region, Bolgatanga, Ghana  
OBJECTIVES: Ghana’s Community-based Health Planning and Service (CHPS) 
initiative to design a system for developing community based health care with 
full participation and support from community members. METHODOLOGY: The 
CHPS initiative scales up strategies developed and tested by a project of the 
Navrongo Health Research Centre in northern Ghana. Launched in 1994 as a 
three village pilot to develop strategies for mobilizing volunteerism, resources, 
and cultural institutions for supporting community-based primary health care, 
the project was expanded to a district-wide four celled trial in 1996. When 
evidence demonstrated that Navrongo strategies reduced childhood mortality, a 
replication project was launched in Nkwanta district to test and develop 
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methods for scale-up. Using evidence from Nkwanta, national scale-up was 
launched in 2000 as a program of exchanges for district teams to work with 
Navrongo and Nkwanta implementers on designing pilot implementation of 
CHPS elsewhere in Ghana. RESULTS: This paper reviews operational 
determinants of this success and implications of the Upper East Region 
experience for efforts to develop evidence-based community health services 
elsewhere in Africa CONCLUSIONS: Although CHPS scale-up has been launched 
in all 170 districts, the Upper East Region remains its lead performing region, 
despite challenging economic, ecological, and social circumstances for health 
development.  
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PHARMACOECONOMICS: NEED TO IMPLEMENT AS A TOOL FOR DRUG 
REIMBURSEMENT IN INDIA  
Janodia M1, Udupa N2, Muragundi PM3, Ligade V4, Dharmagadda S4 
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Manipal 
College of Pharmaceutical Sciences, Manipal, India, 3Manipal College of Pharmaceutical  
Sciences, Manipal, Karnataka, India, 4Manipal College of Pharmceutical Sciences, Manipal, India, 
India  
Health care is one of India’s largest sectors. Private and Public sector spending in 
India is highly skewed towards the private sector accounting for nearly 80% of 
total health care spending in India. However, a major chunk is through out of 
pocket (OOP) expenditure whereas only 11% of population has health insurance. 
About 35% of population is covered by state or central health insurance schemes. 
The public health spending is comparatively low. As a percentage of GDP the 
public health spending has reduced from 1.3% in 1990 to 0.9%. The overall budget 
on drugs and medicines by both central and state governments is only a fraction 
of health sector expenditure. The state expenditure is also not uniform as some 
states are spending about 5% on medicines whereas other states are spending as 
high as 17% on medicines and drugs. Despite these disparities in drug and 
medicine spending among states in India, it is reported that public institutions 
spend inadequate in India. Though the government of India has ceiling on drug 
prices of about 76 drugs, many drugs are out of control and for same drug offered 
by different companies’ different price exist. Due to differences in price of 
various brands of same molecule, access to health care is not uniform. This is an 
issue during reimbursement of drugs. Private health insurance companies do not 
have a list of medicines that would be reimbursed. Thus, private health 
insurance players reimburse different amount to different patients for same 
molecule with different brand names. If pharmacoeconomics is applied as a tool 
to identify the best treatment option, the burden on health care would reduce  
for all stakeholders including patients, insurance companies and the 
government.  
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PATIENT SAFETY PROGRAMME IN KBK DISTRICTS OF ODISHA, INDIA  
Gupta (Bhoi) P1, Saha D2, Bhoi N3 
1Development for Society (DFS) & Free Lancer, Bhubaneshwar, Odisha, India, 2Gayatri Institute of 
Pharmacy, Sambalpur, Subarnapur, India, 3IPE Global, DFID supported Health Sector Reforms 
Programme, Bhubaneshwar, India  
ORGANIZATION: The Development for society (DFS) is an non Governmental 
organization working in undivided KBK districts of Odisha in the area of Health, 
Nutrition, WASH including quality assurance & patient safety in hospitals at 
community level. OBJECTIVES: Patient safety is the absence of preventable harm to 
a patient during the process of health care. The discipline of patient safety is the 
coordinated efforts to prevent harm, caused by the process of health care itself, 
from occurring to patients. The data on frequency and magnitude of avoidable 
adverse patient events in Odisha is not well known. The goal is to create a data base 
on frequency and magnitude of avoidable adverse patient safety events for further 
intervention to improve quality of care. METHODS: Surgical Safety; Hand Hygiene; 
Management of Medication and Patient communication. RESULTS: DFS in 
collaboration with Indian Confederation for Healthcare Accreditation and other 
partners like WHO, patients group, Ministry of Health would create data base on 
patient safety, spell out clear-cut patient safety standards, train employees of 
hospitals (Primary health centres) including doctors & paramedics, ASHA 
(accredited social health activist) at village level, local nursing homes and clinics in 
spotting medical errors and adverse reactions as well as encourage them to report 
the same in order to create a "desi" database and to take suitable mitigation 
measures. CONCLUSION: The Patient safety data created would help in designing 
the standards which would be implemented on pilot basis in KBK districts of 
Odisha with support from Ministry of Health, Government of Odisha & other 
development partners including patient groups which would help in improving the 
quality of care in the PHCs of this regions thereby improving the health care quality 
in the hospitals (PHCs) at community level.  
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PCV1  
CARDIOVASCULAR SAFETY OF CONCURRENT USE OF ATYPICAL 
ANTIPSYCHOTIC AGENTS AND LONG ACTING STIMULANTS IN CHILDREN AND 
ADOLESCENTS DIAGNOSED WITH ATTENTION DEFICIT/HYPERACTIVITY 
DISORDER  
Kamble P1, Aparasu RR1, Chen H1, Johnson ML1, Abughosh S1, Bhatara V2 
1University of Houston, Houston, TX, USA, 2University of South Dakota, Sioux Falls, SD, USA  
OBJECTIVES: The study examined cardiovascular safety of concurrent atypical 
antipsychotic agents and long acting stimulants (LAS) use in children and 
adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). METHODS: 
The study involved retrospective longitudinal analysis of 2003-2007 Medicaid 
Analytical eXtract (MAX) data of four US states. The cohort involved children and 
adolescents aged 6 to 17 years who initiated treatment with LAS for ADHD. The 
continuous eligibility 6 months before and 12 months after the index LAS date 
was ensured for the study cohort. Atypical antipsychotic use was identified after 
the initiation of the index LAS and classified as current use (days of active use), 
former use (days after current use), and nonuse (time before the first use 
including the follow up of those who never exposed to atypicals). The study end 
point was defined as the first inpatient or outpatient claim due to cardiovascular 
event. The risk for cardiovascular event was evaluated using time dependent 
Cox regression analysis. RESULTS: All the study participants were followed for 
9,206,873 person-days of observation period. The numbers of cardiac events were 
840, 202, and 45 during periods of atypical non-use, current use, and former use 
respectively. After controlling for demographic, service related, and clinical 
characteristics, the study found that current users and former users of atypical 
antipsychotics were not associated with cardiovascular events compared to no 
atypical users (Current use: HR, 1.17, 95% CI, 0.98-1.40; Former use: HR, 1.24; 95% 
CI, 0.91-1.69). However, patient characteristics like diagnosis of obesity and 
diabetes, and use of mood stabilizers increased the risk of cardiovascular events. 
CONCLUSIONS: The study did not find any increased cardiovascular risk with 
addition of the atypical antipsychotics to long acting stimulant regimen in 
children and adolescents diagnosed with ADHD.  
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SHORT-TERM CLINICAL AND ECONOMIC CONSEQUENCES OF CORONARY 
STENT THROMBOSIS  
Kohn CG1, Kluger J2, Azeem M2, Coleman CI3 
1University of Connecticut, Hartford, CT, USA, 2Hartford Hospital, Hartford, CT, USA, 3University 
of Connecticut, Storrs, CT, USA  
OBJECTIVES: To conduct a systematic review and meta-analysis to better 
quantify the real-world incidence of in-hospital or 30-day death or myocardial 
infarction (MI) following coronary stent thrombosis (ST), as well as ST-related 
treatment costs. METHODS: We searched Medline, Embase and Scopus from 
January 2000 to July 2012 to identify observational or registry studies that 
evaluated a cohort of ≥25 patients experiencing angiographically-confirmed 
thrombosis of a drug-eluting or bare-metal stent, required the use of dual-
antiplatelet therapy for guideline recommended durations, and reported on the 
incidence of in-hospital or 30-day death or MI and/or ST-related treatment costs. 
Incidences and treatment costs from each study were pooled using random-
effects meta-analysis. Statistical heterogeneity was assessed using the I2statistic 
(>50% deemed significant). RESULTS: A total of 23 studies were included. Among 
the 12 studies (N=8,832 STs) reporting in-hospital mortality, the pooled incidence 
rate was estimated to be 7.9%, 95%CI=5.4%-11.3%, I2=86%. Ten studies (N=1,294 
STs) reported 30-day death, with a pooled incidence of 11.6%, 95%CI=8.8%-15.1%, 
I2=55%. Subgroup analysis suggested patients experiencing early ST (within 30-
days of implant) had higher in-hospital and 30-day mortality than those 
experiencing very-late ST (interaction p<0.04 for both). Stent type (bare-metal vs. 
drug-eluting) had no significant effect on in-hospital or 30-day mortality 
(interaction p>0.22 for both). In the 5 studies (N=542 STs) and 3 studies (N=180 
STs) reporting in-hospital and 30-day MI, respectively, the pooled incidence rates 
were 6.1%, 95%CI=2.1%-16.2%, I2=88% and 9.5%, 95%CI=3.8%-22.0%, I2=65%. Only 
one study reported costs associated with ST, estimating the median/patient cost 
of hospitalization to treat early ST at $11,134 (in 2000US$). CONCLUSIONS: 
Regardless of stent type used, the short-term clinical and economic 
consequences of coronary stent thrombosis (ST) appear significant. While stent 
type does not seem to affect the incidence of post-ST outcomes, an earlier 
occurrence of ST may be associated with higher mortality.  
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RELATIONSHIP BETWEEN MAJOR BLEEDING AND CONCURRENT USE OF 
ANTIPLATELET DRUGS WITH CHINESE MEDICATIONS  
Tsai HH, Lin HW 
China Medical University, Taichung, Taiwan  
OBJECTIVES: While patients use Chinese medications (CM) concurrently with 
Western medications are common in Taiwan, the use of CM products with 
antiplatelet agents might increase the bleeding risks. The objective of this 
research was to explore the impact of major bleeding risk due to concurrent use 
of antiplatelet drugs with CMs ( American ginseng, Asian ginseng, danshen, and 
dong quai). METHODS: A nested case-control and case-crossover study using the 
2007 National Health Insurance Research Databases in Taiwan was conducted. 
All outpatients who used aspirin, clopidogrel, dipyridamole, or ticlopidine 
continuously were included in the cohort. Those antiplatelet users hospitalized 
for major bleeding were in case group and the corresponding control group was 
randomly matched base on the propensity score. The case periods in case-
crossover study were defined as 1-14 days before hospitalization and 15-28 days 
or 71-84 days before hospitalization were control periods. The conditional 
logistic regression analyses were performed to determine the associations 
between major bleeding and exposure to interactions between antiplatelets and 
specific CM. RESULTS: Of the 92,046 antiplatelet users as the cohort, 1,095 
patients (1.19%) were identified as cases and 887 patients were included in the 
case-crossover study. Concurrent use of antiplatelet drugs with specific single 
CM showed an increased risk of hospitalization due to major bleeding in both 
studies but was not statistically significant. Antiplatelet drugs users were 28% to 
152% more risk of major bleeding among those who used Asian ginseng or 
danshen currently than others. CONCLUSIONS: Relationship between major 
bleeding and concurrent use of antiplatelet drugs with CM was not ascertained. 
The adverse clinical outcomes due to concomitant use warrant further 
investigation.  
